c-Jun knockdown sensitizes osteosarcoma to doxorubicin

摘要

The oncogene c-Jun has been found to be up-regulated in\uda variety of cancers, including osteosarcoma. Doxorubicin\udis a frontline chemotherapeutic against osteosarcoma, but\udis limited by toxicity. DNAzymes are oligonucleotides\udcapable of specific catalysis of target mRNA. A biocompatible\udc-Jun DNAzyme nanoparticle formulated from\udchitosan regressed the growth and metastasis of preestablished\udtumors, especially in combination with doxorubicin.\udIn vitro data confirmed that c-Jun knockdown\udchemosensitized these cells to doxorubicin treatment.\udc-Jun down-regulation–mediated tumor inhibition also led\udto concomitant decreased osteolysis. Clinically, knockdown\udof c-Jun with chitosan nanobiotechnology may\udproffer an improved treatment outcome for osteosarcoma.